Brief: Verve Therapeutics Announces Pipeline Progress And Expansion

Verve Therapeutics

15/05/2023 11:45

May 15 (Reuters) - Verve Therapeutics Inc  VERV.O :
    * VERVE THERAPEUTICS ANNOUNCES PIPELINE PROGRESS AND
EXPANSION AND
REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
    * WELL-CAPITALIZED WITH $508.7 MILLION SUPPORTING RUNWAY
INTO
SECOND HALF OF 2025
    * HEART-1 CLINICAL TRIAL OF VERVE-101 ONGOING WITH INITIAL
DATA
EXPECTED IN SECOND HALF OF 2023
    * QTRLY NET LOSS PER SHARE $0.84
    * VERVE-201 TARGETING ANGPTL3 PROGRESSING WITH CLINICAL
TRIAL
INITIATION EXPECTED IN SECOND HALF OF 2024
    * Q1 EARNINGS PER SHARE VIEW $-0.78 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX5XKn6Y 
Further company coverage:  VERV.O